Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...

California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin Newsom's initial timeline.

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...

The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

February 26, 2025Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.85. Operator: Hello. Welcome to Vir Biotechnology’s Fourth Quarter and Full Year ...

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported ...

On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose ...